Before Invest
GILEAD SCIENCES, INC. logo

GILEAD SCIENCES, INC.

GILD
Biological Products No Disgnostic Substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 40 quarters
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Jun 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Revenues:
                                                    
Product sales
-
-
-
-
-
-
-
-
-
-
-
-
Royalty revenues
-
-
-
-
-
-
-
-
-
-
-
-
Royalty, contract and other revenues
-
-
-
-
-
-
-
-
-
-
-
-
Total revenues
7,803
6,960
7,769
7,082
6,667
7,545
6,954
6,686
7,051
6,599
6,352
7,042
Costs and expenses:
                                                    
Cost of goods sold
1,579
1,445
1,569
1,501
1,540
1,574
1,544
1,552
1,565
1,442
1,401
1,395
Research and development expenses
1,764
1,372
1,346
1,491
1,379
1,395
1,351
1,520
1,457
1,407
1,447
1,149
Acquired in-process research and development expenses
11,183
107
170
61
253
505
38
4,131
91
236
481
448
In-process research and development impairments
1,750
-
0
190
0
1,750
0
2,430
0
0
0
0
Selling, general and administrative expenses
1,921
1,451
1,357
1,365
1,258
1,433
1,377
1,375
1,315
1,849
1,319
1,213
Total costs and expenses
18,197
4,374
4,442
4,608
4,430
6,657
4,309
11,008
4,428
4,934
4,647
4,205
Operating (loss) income
(10,394)
2,586
3,327
2,474
2,237
888
2,644
(4,322)
2,623
1,665
1,705
2,837
Interest expense
(247)
(240)
(256)
(254)
(260)
(238)
(237)
(254)
(232)
(230)
(230)
(229)
Other (income) expense, net
387
235
569
208
(328)
306
(355)
91
(72)
152
(174)
(176)
(Loss) income before income taxes
(10,254)
2,580
3,641
2,429
1,649
956
2,053
(4,486)
2,318
1,588
1,300
2,432
Income tax expense
242
559
589
468
334
(297)
438
(315)
146
549
316
646
Net income (loss)
-
-
3,052
1,960
1,315
1,253
1,614
(4,170)
2,172
1,039
985
1,786
Net income attributable to noncontrolling interest
-
-
0
0
0
0
0
0
(8)
(6)
(26)
(3)
Net (loss) income
$ (10,496)
$ 2,021
$ 3,052
$ 1,960
$ 1,315
$ 1,253
$ 1,614
$ (4,170)
$ 2,180
$ 1,045
$ 1,010
$ 1,789
Basic (loss) earnings per share (in dollars per share)
$ (8.45)
$ 1.63
$ 2.46
$ 1.57
$ 1.06
$ 1
$ 1.29
$ (3.34)
$ 1.75
$ 0.84
$ 0.81
$ 1.43
Diluted (loss) earnings per share (in dollars per share)
(8.45)
1.61
2.43
1.56
1.04
1
1.29
(3.34)
1.73
0.83
0.8
1.42
Shares used in basic (loss) earnings per share calculation (in shares)
1,243
1,242
1,243
1,245
1,246
1,247
1,247
1,247
1,248
1,249
1,248
1,255
Shares used in diluted (loss) earnings per share calculation (in shares)
1,243
1,254
1,254
1,255
1,259
1,254
1,251
1,247
1,257
1,258
1,261
1,261
Cash dividends declared (usd per share)
-
-
-
-
-
-
-
-
-
-
-
-